Compare · GLP-1 agonist
Retatrutide vs VK2735
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Retatrutide | VK2735 | |
|---|---|---|
| Evidence | Preliminary human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results. | VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown. |
| Full profile → | Full profile → |
Retatrutide
Retatrutide (Lilly code LY3437943) is an investigational injectable drug for obesity and type 2 diabetes. It has produced some of the largest weight-loss figures seen in trials so far, but as of June 2026 it is not approved anywhere and its pivotal Phase 3 data have not yet been peer-reviewed.
VK2735
VK2735 is an investigational obesity drug from Viking Therapeutics. It belongs to the incretin class — the same broad family as semaglutide and tirzepatide — and has generated a lot of attention because its early human data look strong and because Viking is developing both an injectable and an oral…